

## Chemotherapy drug regimens as part of the AIM Oncology/Cancer Care Quality Program

| Regimen Name   | Pathway Pathologies | Pathway Stages    | Pathway BioMarkers         | Pathway Line of Treatment | Pathologies    | Consensus Group(s)  |
|--|---------------------|-------------------|----------------------------|---------------------------|----------------|---|
| Zytiga (Abiraterone Acetate) and Prednisone (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)                          | Adenocarcinoma      | IVB;<br>Recurrent | Castration-resistant - No  | First Line +              | Adenocarcinoma | FDA; NCCN Category 1  |
| Zytiga (Abiraterone Acetate) (1000 mg); Prednisone and Zoladex (Goserelin) (Castration Sensitive/Naïve; High Risk; Stage IVB/Recurrent)  | Adenocarcinoma      | IVB;<br>Recurrent | Castration-resistant - No  | First Line +              | Adenocarcinoma | FDA; NCCN Category 1  |
| Zytiga (Abiraterone Acetate); Prednisone and Lupron (Leuprolide Acetate) (Castration Sensitive/Naïve; High Risk; Stage IVB/Recurrent)    | Adenocarcinoma      | IVB;<br>Recurrent | Castration-resistant - No  | First Line +              | Adenocarcinoma | FDA; NCCN Category 1  |
| Zytiga (Abiraterone Acetate); Prednisone and Trelstar (Triptorelin Pamoate) (Castration Sensitive/Naïve; High Risk; Stage IVB/Recurrent) | Adenocarcinoma      | IVB;<br>Recurrent | Castration-resistant - No  | First Line +              | Adenocarcinoma | FDA; NCCN Category 1  |
| Zytiga (Abiraterone Acetate) and Prednisone (Castration Resistant; Metastatic; First Line)   | Adenocarcinoma      | IVB;<br>Recurrent | Castration-resistant - Yes | First Line                | Adenocarcinoma | FDA; NCCN Category 1;<br>NCCN Category 2A                   |
| Zytiga (Abiraterone) (1000mg) and Prednisone (Metastatic; Second Line or Greater)  | Adenocarcinoma      | IVB;<br>Recurrent |                            | Second Line +             | Adenocarcinoma | FDA; NCCN Category 1;<br>NCCN Category 2A; NCCN Category 2B |
| Zytiga (Abiraterone Acetate) with Zoladex (Goserelin Acetate) (Castration-Resistant; Metastatic/Recurrent; 1st Line or Greater)          | Adenocarcinoma      | IVB;<br>Recurrent | Castration-resistant - Yes | First Line +              | Adenocarcinoma |   |

|  |   |                   |  |              |   |                           |
|--|---|-------------------|--|--------------|---|---------------------------|
| Zytiga (Abiraterone Acetate) with Lupron (Leuprolide Acetate) (Castration-Resistant; Metastatic/Recurrent; 1st Line or Greater)    | Adenocarcinoma  | IVB;<br>Recurrent | Castration-resistant - Yes   | First Line + | Adenocarcinoma  |                           |
| Zytiga (Abiraterone Acetate) with Trelstar (Triptorelin Pamoate) (Castration-Resistant; Metastatic/Recurrent; 1st Line or Greater) | Adenocarcinoma  | IVB;<br>Recurrent | Castration-resistant - Yes   | First Line + | Adenocarcinoma  |                           |
| Arimidex (Anastrozole) (Palliative; Stage IV or Recurrent)   | Adenocarcinoma;<br>Adenoid Cystic Carcinoma;<br>Inflammatory Carcinoma;<br>Invasive Ductal Carcinoma;<br>Invasive Lobular Carcinoma;<br>Invasive Metaplastic Carcinoma;<br>Medullary Carcinoma;<br>Mucinous (Colloid) Carcinoma;<br>Papillary Carcinoma; Spindle Cell Carcinoma;<br>Tubular Carcinoma | IV;<br>Recurrent  | Progesterone Receptor - Positive; Menopausal Status - Post-menopausal;<br>Estrogen Receptor - Positive | First Line + | Adenocarcinoma;<br>Adenoid Cystic Carcinoma;<br>Inflammatory Carcinoma;<br>Invasive Ductal Carcinoma;<br>Invasive Lobular Carcinoma;<br>Invasive Metaplastic Carcinoma;<br>Medullary Carcinoma;<br>Mucinous (Colloid) Carcinoma;<br>Papillary Carcinoma; Spindle Cell Carcinoma;<br>Tubular Carcinoma | NCCN Category 2A; NCI-PDQ |

|   |   |                          |  |                     |   |                         |
|---|---|--------------------------|--|---------------------|---|-------------------------|
| <p>Arimidex (Anastrozole)<br/>With Monthly Zoladex<br/>(Goserelin)</p>  | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor -<br/>Positive; Menopausal<br/>Status - Peri-menopausal;<br/>Menopausal Status - Pre-<br/>menopausal; Menopausal<br/>Status - Does Not Apply-<br/>Patient is Male; Estrogen<br/>Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 2A</p> |
| <p>Arimidex (Anastrozole) with<br/>Monthly Leuprolide (3.75<br/>mg)</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor -<br/>Positive; Menopausal<br/>Status - Peri-menopausal;<br/>Menopausal Status - Pre-<br/>menopausal; Menopausal<br/>Status - Does Not Apply-<br/>Patient is Male; Estrogen<br/>Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 2A</p> |

|  |  |                |  |              |  |                  |
|--|--|----------------|--|--------------|--|------------------|
| Arimidex (Anastrozole) with Monthly Leuprolide (7.5 mg)  | Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma | IV; Recurrent  | Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive | First Line + | Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma | NCCN Category 2A |
| Erleada (Apalutamide) (Castration Sensitive; Metastatic/Recurrent First Line or Greater)                                     | Adenocarcinoma   | IVB; Recurrent | Castration-resistant - No  | First Line + | Adenocarcinoma   | NCCN Category 1  |
| Erleada (Apalutamide) and Zoladex (Goserelin Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)    | Adenocarcinoma   | IVB, Recurrent | Castration-resistant - No  | First Line + | Adenocarcinoma   | NCCN Category 1  |
| Erleada (Apalutamide) and Lupron (Leuprolide Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)    | Adenocarcinoma   | IVB, Recurrent | Castration-resistant - No  | First Line + | Adenocarcinoma   | NCCN Category 1  |
| Erleada (Apalutamide) and Trelstar (Triptorelin Pamoate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater) | Adenocarcinoma   | IVB, Recurrent | Castration-resistant - No  | First Line + | Adenocarcinoma   | NCCN Category 1  |

|  |                |                          |                            |              |                |                                     |
|--|----------------|--------------------------|----------------------------|--------------|----------------|-------------------------------------|
| Clarithromycin and Amoxicillin (Gastric MALT; H-Pylori Positive; First Line) (W)   | MALT - Gastric | IA-E, IB-E, IIA-E, IIB-E |                            | First Line   | MALT - Gastric |                                     |
| Clarithromycin and Metronidazole (Gastric MALT; H-Pylori Positive; First Line)   | MALT - Gastric | IA-E, IB-E, IIA-E, IIB-E |                            | First Line   | MALT - Gastric |                                     |
| Xtandi (Enzalutamide) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)                                    | Adenocarcinoma | IVB; Recurrent           | Castration-resistant - No  | First Line + | Adenocarcinoma | FDA; NCCN Category 1                |
| Xtandi (Enzalutamide) (Metastatic; 1st Line)   | Adenocarcinoma | IVB; Recurrent           | Castration-resistant - Yes | First Line   | Adenocarcinoma | ASCO; FDA; NCCN Category 1; NCI-PDQ |
| Xtandi (Enzalutamide) and Zoladex (Goserelin Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)    | Adenocarcinoma | IVB, Recurrent           | Castration-resistant - No  | First Line + | Adenocarcinoma | NCCN Category 1                     |
| Xtandi (Enzalutamide) and Lupron (Leuprolide Acetate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater)    | Adenocarcinoma | IVB, Recurrent           | Castration-resistant - No  | First Line + | Adenocarcinoma | NCCN Category 1                     |
| Xtandi (Enzalutamide) and Trelstar (Triptorelin Pamoate) (Castration Sensitive; Metastatic/Recurrent; First Line or Greater) | Adenocarcinoma | IVB, Recurrent           | Castration-resistant - No  | First Line + | Adenocarcinoma | NCCN Category 1                     |

|  |   |                          |  |  |   |                                       |
|--|---|--------------------------|--|--|---|---------------------------------------|
| <p>Aromasin (Exemestane)<br/>(Stage IV or Recurrent;<br/>Palliative)</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor -<br/>Positive; Menopausal<br/>Status - Post-menopausal;<br/>Estrogen Receptor -<br/>Positive</p>   | <p>Second Line +</p>                                 | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 2A; NCI-<br/>PDQ</p> |
| <p>Aromasin (Exemestane)<br/>With Monthly Goserelin</p>                  | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor -<br/>Positive; Menopausal<br/>Status - Peri-menopausal;<br/>Menopausal Status - Pre-<br/>menopausal; Menopausal<br/>Status - Does Not Apply-<br/>Patient is Male; Estrogen<br/>Receptor - Positive</p> | <p>Second Line,<br/>Third Line,<br/>Third Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 2A; NCI-<br/>PDQ</p> |

|  |   |                          |  |  |   |                                       |
|--|---|--------------------------|--|--|---|---------------------------------------|
| <p>Aromasin (Exemestane)<br/>With Monthly Leuprolide<br/>(3.75 mg)</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor -<br/>Positive; Menopausal<br/>Status - Peri-menopausal;<br/>Menopausal Status - Pre-<br/>menopausal; Menopausal<br/>Status - Does Not Apply-<br/>Patient is Male; Estrogen<br/>Receptor - Positive</p> | <p>Second Line,<br/>Third Line,<br/>Third Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 2A; NCI-<br/>PDQ</p> |
| <p>Aromasin (Exemestane)<br/>With Monthly Leuprolide<br/>(7.5 mg)</p>  | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor -<br/>Positive; Menopausal<br/>Status - Peri-menopausal;<br/>Menopausal Status - Pre-<br/>menopausal; Menopausal<br/>Status - Does Not Apply-<br/>Patient is Male; Estrogen<br/>Receptor - Positive</p> | <p>Second Line,<br/>Third Line,<br/>Third Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic<br/>Carcinoma;<br/>Inflammatory<br/>Carcinoma;<br/>Invasive Ductal<br/>Carcinoma;<br/>Invasive Lobular<br/>Carcinoma;<br/>Invasive<br/>Metaplastic<br/>Carcinoma;<br/>Medullary<br/>Carcinoma;<br/>Mucinous (Colloid)<br/>Carcinoma;<br/>Papillary<br/>Carcinoma; Spindle<br/>Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 2A; NCI-<br/>PDQ</p> |

|  |   |                          |  |                     |   |  |
|--|---|--------------------------|--|---------------------|---|--|
| <p>Faslodex (Fulvestrant) 500 mg</p>                       | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor - Positive; Estrogen Receptor - Positive</p>                                      | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 1; NCCN Category 2A</p> |
| <p>Faslodex (Fulvestrant) (No Prior Endocrine Therapy)</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor - Positive; Menopausal Status - Post-menopausal; Estrogen Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>FDA; NCCN Category 1</p>              |



|   |   |                          |   |                     |   |  |
|---|---|--------------------------|---|---------------------|---|--|
| <p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment With Goserelin</p>                             | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 1; NCCN Category 2A</p> |
| <p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment with Monthly Lupron (Leuprolide) (3.75 mg)</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 1; NCCN Category 2A</p> |

|  |   |                          |   |                     |   |  |
|--|---|--------------------------|---|---------------------|---|--|
| <p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment with Monthly Lupron (Leuprolide) (7.5 mg)</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 1; NCCN Category 2A</p> |
| <p>Faslodex (Fulvestrant) 250 mg reduced dose for Patients with Liver Impairment</p>   | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor - Positive; Estrogen Receptor - Positive</p>   | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 1; NCCN Category 2A</p> |

|   |   |                          |   |                     |   |  |
|---|---|--------------------------|---|---------------------|---|--|
| <p>Faslodex (Fulvestrant) with Monthly Goserelin</p>            | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 1; NCCN Category 2A</p> |
| <p>Faslodex (Fulvestrant) with Monthly Leuprolide (3.75 mg)</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 1; NCCN Category 2A</p> |

|  |  |                                 |  |              |  |  |
|--|--|---------------------------------|--|--------------|--|--|
| Faslodex (Fulvestrant) with Monthly Leuprolide (7.5 mg)  | Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma | IV; Recurrent                   | Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive | First Line + | Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma | NCCN Category 1; NCCN Category 2A          |
| Zoladex (Goserelin Acetate) (For 1-3 Years) (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line)                              | Adenocarcinoma   | IIC; III; IIIA; IIIB; IIIC; IVA | Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional  | First Line   | Adenocarcinoma   | NCCN Category 1; NCCN Category 2A; NCI-PDQ |
| Zoladex (Goserelin Acetate) for 1-3 years with Bicalutamide or Flutamide (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line) | Adenocarcinoma   | IIC; III; IIIA; IIIB; IIIC; IVA | Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional  | First Line   | Adenocarcinoma   | NCCN Category 1; NCCN Category 2A; NCI-PDQ |
| Zoladex (Goserelin Acetate) For 4-6 Months (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)                       | Adenocarcinoma   | IIA; IIB; IIC                   | Prostate Cancer Recurrence Risk - Unfavorable Intermediate   | First Line   | Adenocarcinoma   | AUA; NCCN Category 2A                      |

|   |                |                                 |   |                          |                |                                      |
|---|----------------|---------------------------------|---|--------------------------|----------------|--------------------------------------|
| Zoladex (Goserelin Acetate) For 4-6 Months With Bicalutamide or Flutamide (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line) | Adenocarcinoma | IIA; IIB; IIC                   | Prostate Cancer Recurrence Risk - Unfavorable Intermediate  | First Line               | Adenocarcinoma | AUA; NCCN Category 2A                |
| Zoladex (Goserelin Acetate) For 6 months (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line)  | Adenocarcinoma | IIC; III; IIIA; IIIB; IIIC; IVA | Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional | First Line               | Adenocarcinoma | NCI-PDQ                              |
| Zoladex (Goserelin Acetate) For 6 months with Bicalutamide or Flutamide (Stages IIC-IVA) (High/Very High/Regional Risk; 1st Line)           | Adenocarcinoma | IIC; III; IIIA; IIIB; IIIC; IVA | Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional | First Line               | Adenocarcinoma | NCI-PDQ                              |
| Zoladex (Goserelin Acetate) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)  | Adenocarcinoma | IVB, Recurrent                  | Castration-resistant - No   | First Line +             | Adenocarcinoma | ASCO; FDA; NCCN Category 2A; NCI-PDQ |
| Zoladex (Goserelin Acetate) Post Prostatectomy with Positive Nodes  | Adenocarcinoma | IVA                             |   | Adjuvant/ Post-operative | Adenocarcinoma | NCCN Category 1                      |
| Zoladex (Goserelin Acetate) and Casodex (Bicalutamide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)                                 | Adenocarcinoma | IVB, Recurrent                  | Castration-resistant - Yes  | First Line +             | Adenocarcinoma | ASCO; FDA; NCCN Category 2A; NCI-PDQ |
| Zoladex (Goserelin Acetate) with Bicalutamide or Flutamide (Up to 60 Days for Flare) (Advanced/Metastatic/Recurrent; 1st Line or Greater)   | Adenocarcinoma | IVB, Recurrent                  |   | First Line +             | Adenocarcinoma | ASCO; FDA; NCCN Category 2A          |

|  |   |                  |  |              |   |                       |
|--|---|------------------|--|--------------|---|-----------------------|
| Femara (Letrozole) (Stage IV or Recurrent; Palliative) | Adenocarcinoma;<br>Adenoid Cystic Carcinoma;<br>Inflammatory Carcinoma;<br>Invasive Ductal Carcinoma;<br>Invasive Lobular Carcinoma;<br>Invasive Metaplastic Carcinoma;<br>Medullary Carcinoma;<br>Mucinous (Colloid) Carcinoma;<br>Papillary Carcinoma; Spindle Cell Carcinoma;<br>Tubular Carcinoma | IV;<br>Recurrent | Progesterone Receptor - Positive; Menopausal Status - Post-menopausal;<br>Estrogen Receptor - Positive   | First Line + | Adenocarcinoma;<br>Adenoid Cystic Carcinoma;<br>Inflammatory Carcinoma;<br>Invasive Ductal Carcinoma;<br>Invasive Lobular Carcinoma;<br>Invasive Metaplastic Carcinoma;<br>Medullary Carcinoma;<br>Mucinous (Colloid) Carcinoma;<br>Papillary Carcinoma; Spindle Cell Carcinoma;<br>Tubular Carcinoma | FDA; NCCN Category 2A |
| Femara (Letrozole) with Monthly Goserelin              | Adenocarcinoma;<br>Adenoid Cystic Carcinoma;<br>Inflammatory Carcinoma;<br>Invasive Ductal Carcinoma;<br>Invasive Lobular Carcinoma;<br>Invasive Metaplastic Carcinoma;<br>Medullary Carcinoma;<br>Mucinous (Colloid) Carcinoma;<br>Papillary Carcinoma; Spindle Cell Carcinoma;<br>Tubular Carcinoma | IV;<br>Recurrent | Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive | First Line + | Adenocarcinoma;<br>Adenoid Cystic Carcinoma;<br>Inflammatory Carcinoma;<br>Invasive Ductal Carcinoma;<br>Invasive Lobular Carcinoma;<br>Invasive Metaplastic Carcinoma;<br>Medullary Carcinoma;<br>Mucinous (Colloid) Carcinoma;<br>Papillary Carcinoma; Spindle Cell Carcinoma;<br>Tubular Carcinoma | NCCN Category 2A      |

|   |   |                          |   |                     |   |                         |
|---|---|--------------------------|---|---------------------|---|-------------------------|
| <p>Femara (Letrozole) with Monthly Leuprolide (3.75 mg)</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 2A</p> |
| <p>Femara (Letrozole) With Monthly Leuprolide (7.5 mg)</p>  | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>IV;<br/>Recurrent</p> | <p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma;<br/>Adenoid Cystic Carcinoma;<br/>Inflammatory Carcinoma;<br/>Invasive Ductal Carcinoma;<br/>Invasive Lobular Carcinoma;<br/>Invasive Metaplastic Carcinoma;<br/>Medullary Carcinoma;<br/>Mucinous (Colloid) Carcinoma;<br/>Papillary Carcinoma; Spindle Cell Carcinoma;<br/>Tubular Carcinoma</p> | <p>NCCN Category 2A</p> |

|  |                |                                 |   |            |                |  |
|--|----------------|---------------------------------|---|------------|----------------|--|
| Eligard (Leuprolide) 1-3 Years with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)     | Adenocarcinoma | IIC; III; IIIA; IIIB; IIIC; IVA | Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional | First Line | Adenocarcinoma | NCCN Category 1; NCCN Category 2A          |
| Lupron (Leuprolide) For 1-3 Years (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)                                 | Adenocarcinoma | IIC; III; IIIA; IIIB; IIIC; IVA | Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional | First Line | Adenocarcinoma | NCCN Category 1; NCCN Category 2A          |
| Lupron (Leuprolide) For 1-3 Years with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)  | Adenocarcinoma | IIC; III; IIIA; IIIB; IIIC; IVA | Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional | First Line | Adenocarcinoma | NCCN Category 1; NCCN Category 2A; NCI-PDQ |
| Lupron (Leuprolide) For 4-6 Months (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line)                                | Adenocarcinoma | IIC; III; IIIA; IIIB; IIIC; IVA | Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional | First Line | Adenocarcinoma | NCI-PDQ                                    |
| Lupron (Leuprolide) For 4-6 Months (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)                                     | Adenocarcinoma | IIA; IIB; IIC                   | Prostate Cancer Recurrence Risk - Unfavorable Intermediate  | First Line | Adenocarcinoma | NCCN Category 2A                           |
| Lupron (Leuprolide) For 4-6 Months with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk of Recurrence; 1st Line) | Adenocarcinoma | IIC; III; IIIA; IIIB; IIIC; IVA | Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional | First Line | Adenocarcinoma | NCI-PDQ                                    |
| Lupron (Leuprolide) For 4-6 Months With Bicalutamide or Flutamide (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)      | Adenocarcinoma | IIA; IIB; IIC                   | Prostate Cancer Recurrence Risk - Unfavorable Intermediate  | First Line | Adenocarcinoma | NCCN Category 2A                           |



|   |  |                |                                    |                          |  |                                      |
|---|--|----------------|------------------------------------|--------------------------|--|--------------------------------------|
| Lupron (Leuprolide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)  | Adenocarcinoma   | IVB, Recurrent | Castration-resistant - No          | First Line +             | Adenocarcinoma   | ASCO; FDA; NCCN Category 2A; NCI-PDQ |
| Lupron (Leuprolide Acetate) Post Prostatectomy with Positive Nodes  | Adenocarcinoma   | IVA            |                                    | Adjuvant/ Post-operative | Adenocarcinoma   | NCCN Category 1                      |
| Lupron (Leuprolide) and Casodex (Bicalutamide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)                                       | Adenocarcinoma   | IVB, Recurrent | Castration-resistant - Yes         | First Line +             | Adenocarcinoma   | ASCO; FDA; NCCN Category 2A          |
| Lupron (Leuprolide Acetate) with Bicalutamide or Flutamide (Up to 60 Days For Flare) (Advanced/Metastatic/Recurrent; 1st Line or Greater) | Adenocarcinoma   | IVB, Recurrent |                                    | First Line +             | Adenocarcinoma   | ASCO; FDA; NCCN Category 2A          |
| Tamoxifen (Stage IV or Recurrent; 1st Line or Greater)  | Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma | IV; Recurrent  | Menopausal Status - Pre-menopausal | First Line +             | Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma | FDA; NCCN Category 2A; NCI-PDQ       |

|   |   |                      |  |                     |   |  |
|---|---|----------------------|--|---------------------|---|--|
| <p>Tamoxifen (Recurrent; First Line or Greater)</p>   | <p>Adenocarcinoma; Cystadenocarcinoma; Endometroid Carcinoma; Epithelial Cancer; Mucinous Cystadenocarcinoma; Primary Peritoneal; Serous Cystadenocarcinoma</p>   | <p>Recurrent</p>     | <p>Platinum Resistant/Refractory - Yes</p>   | <p>First Line +</p> | <p>Adenocarcinoma; Cystadenocarcinoma; Endometroid Carcinoma; Epithelial Cancer; Mucinous Cystadenocarcinoma; Primary Peritoneal; Serous Cystadenocarcinoma</p>   | <p>NCCN Category 2A; NCCN Category 2B; NCI-PDQ</p> |
| <p>Tamoxifen with Monthly Goserelin (Premenopausal; Stage IV or Recurrent; 1st Line or Greater)</p> | <p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p> | <p>IV; Recurrent</p> | <p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Premenopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p> | <p>FDA; NCCN Category 2A; NCI-PDQ</p>              |

|   |   |  |   |                     |   |                                       |
|---|---|--|---|---------------------|---|---------------------------------------|
| <p>Tamoxifen with Monthly Leuprolide (7.5 mg) (Stage IV or Recurrent; 1st Line or Greater) (W)</p>            | <p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p> | <p>IA; IB; IIA; IIB; IIIA; IIIB; IIIC; IV; Recurrent</p> | <p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p> | <p>FDA; NCCN Category 2A; NCI-PDQ</p> |
| <p>Tamoxifen with Monthly Lupron (Leuprolide Acetate) (3.75) (Stages I-IV/Recurrent; 1st Line or Greater)</p> | <p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p> | <p>IA; IB; IIA; IIB; IIIA; IIIB; IIIC; IV; Recurrent</p> | <p>Progesterone Receptor - Positive; Menopausal Status - Peri-menopausal; Menopausal Status - Pre-menopausal; Menopausal Status - Does Not Apply- Patient is Male; Estrogen Receptor - Positive</p> | <p>First Line +</p> | <p>Adenocarcinoma; Adenoid Cystic Carcinoma; Inflammatory Carcinoma; Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Invasive Metaplastic Carcinoma; Medullary Carcinoma; Mucinous (Colloid) Carcinoma; Papillary Carcinoma; Spindle Cell Carcinoma; Tubular Carcinoma</p> | <p>FDA; NCCN Category 2A; NCI-PDQ</p> |

|  |                |                                 |   |                          |                |  |
|--|----------------|---------------------------------|---|--------------------------|----------------|--|
| Trelstar (Triptorelin) Post Prostatectomy with Positive Nodes  | Adenocarcinoma | IVA                             |   | Adjuvant/ Post-operative | Adenocarcinoma | NCCN Category 1                            |
| Trelstar (Triptorelin Pamoate) (For 1-3 Years) (Stages IIC-IVA; High/Very High/Regional Risk; 1st Line)  | Adenocarcinoma | IIC; III; IIIA; IIIB; IIIC; IVA | Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional | First Line               | Adenocarcinoma | NCCN Category 1; NCCN Category 2A; NCI-PDQ |
| Trelstar (Triptorelin Pamoate) For 1-3 Years with Bicalutamide or Flutamide (Stages IIC-IVA; High/Very High/Regional Risk; 1st Line)             | Adenocarcinoma | IIC; III; IIIA; IIIB; IIIC; IVA | Prostate Cancer Recurrence Risk - High; Prostate Cancer Recurrence Risk - Very High; Prostate Cancer Recurrence Risk - Regional | First Line               | Adenocarcinoma | NCCN Category 1; NCCN Category 2A; NCI-PDQ |
| Trelstar (Triptorelin Pamoate) (For 4-6 Months) (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line)                                | Adenocarcinoma | IIA; IIB; IIC                   | Prostate Cancer Recurrence Risk - Unfavorable Intermediate  | First Line               | Adenocarcinoma | NCCN Category 2A                           |
| Trelstar (Triptorelin Pamoate) (For 4-6 Months) With Bicalutamide or Flutamide (Stage II; Unfavorable Intermediate Risk of Recurrence; 1st Line) | Adenocarcinoma | IIA; IIB; IIC                   | Prostate Cancer Recurrence Risk - Unfavorable Intermediate  | First Line               | Adenocarcinoma | NCCN Category 2A                           |
| Trelstar (Triptorelin Pamoate) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)  | Adenocarcinoma | IVB, Recurrent                  | Castration-resistant - No   | First Line +             | Adenocarcinoma | ASCO; FDA; NCCN Category 2A; NCI-PDQ       |
| Trelstar (Triptorelin Pamoate) with Casodex (Bicalutamide) (IVA-IVB/Recurrent; Palliative; 1st Line or Greater)                                  | Adenocarcinoma | IVB, Recurrent                  | Castration-resistant - Yes  | First Line +             | Adenocarcinoma | ASCO; FDA; NCCN Category 2A                |

|   |                |                   |  |              |                |                                |
|---|----------------|-------------------|--|--------------|----------------|--------------------------------|
| Trelstar (Triptorelin Pamoate) with Bicalutamide or Flutamide (Up to 60 Days For Flare)<br>(Advanced/Metastatic/Recurrent; 1st Line or Greater) | Adenocarcinoma | IVB,<br>Recurrent |  | First Line + | Adenocarcinoma | ASCO; FDA; NCCN<br>Category 2A |
|---|----------------|-------------------|--|--------------|----------------|--------------------------------|